Newswise — KALAMAZOO, Mich., May 6, 2014 -- Ablative Solutions, Inc. (ASI), a privately held company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has added Paul Sobotka, MD, FACP, FACC, FAHA, a highly respected clinician, to its Scientific Advisory Board. The Company is developing a patented device for sympathetic nerve modulation, the Peregrine System™, which delivers treatment to the outer region of arteries, including renal arteries, where the sympathetic nerves are located. The interruption of these nerve pathways may have therapeutic implications for hypertension, metabolic syndrome, congestive heart failure and obesity.
Paul Sobotka, MD, FACP, FACC, FAHA, is Clinical Professor of Medicine/Cardiology at Ohio State University and is an expert in sympathetic nerve modulation and hypertension, having served as Chief Medical Officer at Ardian, Inc., and having played a very active role in basic and clinical research in this field. "Ablative Solutions has assembled an exceptional group of scientific advisors with a long track record of innovation, and I am honored to be a part of this creative group," states Dr. Sobotka. "Combining the Peregrine System technology with this dynamic Ablative Solutions team is exciting. I am confident that we can create new products that will address our patients' healthcare needs and improve the choices available to safely and effectively treat their chronic illnesses."
Dr. Sobotka joins a distinguished Scientific Advisory Board that includes:
- William Abraham, MD, FACC, Chief of Cardiovascular Medicine, Ohio State University
- Steven Almany, MD, FACC, FSCAI, Medical Director of Beaumont Hospital System, Associate Professor, Beaumont Oakland University School of Medicine, Rochester, MI
- Maurice Buchbinder, MD, FACC, Foundation for Cardiovascular Medicine, San Diego, CADean Kereiakes, MD, FACC, FSCAI, Medical Director, The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, OH
- R. Stefan Kiesz, MD, FACC, FSCAI, FESC, President & CEO, San Antonio Endovascular & Heart Institute; Co-Founder, American Heart of PolandRobert Schwartz, MD, FACC, Professor of Medicine, University of Minnesota, Cardiologist at Minneapolis Heart Institute
"We are honored to have Dr. Sobotka join our esteemed group of scientific and clinical advisors," said Tim Fischell, MD, CEO of Ablative Solutions. "This visionary group's track record in exploring ways to improve therapy will play a vital role as we investigate the diseases that might benefit from sympathetic nerve modulation via perivascular chemical denervation with the Peregrine System."
ASI was founded by two proven medical device entrepreneurs, Tim Fischell, MD, and David Fischell, PhD. Development efforts have been led by ASI president, Vartan Ghazarossian, PhD, whose executive experience in both biopharmaceutical and medical device companies has added significant value to novel device-chemistry combination therapy. The Peregrine System uses a unique, patent-pending technology to deliver diagnostic and therapeutic agents directly to the perivascular layer that surrounds blood vessels.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in this offering. There will not be any sale of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.Forward-Looking Statements Statements made in this press release that look forward in time or that express expectations regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and market acceptance of the Company's products to patients, intellectual property protection, and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. As a result, you are cautioned not to put any undue reliance on any forward-looking statement. Except as required by law, the Company assumes no obligation to update the forward-looking statements, which are made as of the date hereof, even if new information becomes available in the future.